COYA 301
Alternative Names: COYA-301; LD IL-2; Low-dose IL-2Latest Information Update: 28 Jun 2026
At a glance
- Originator ARScience Bio
- Developer Coya Therapeutics
- Class Antidementias; Antiparkinsonians; Cytokines; Interleukins; Neuroprotectants
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Preclinical Parkinson's disease
- No development reported Frontotemporal dementia
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Frontotemporal dementia in USA (SC)
- 06 Feb 2025 Pharmacodynamics data from a phase-II clinical trials in Alzheimer's disease released by Coya Therapeutics
- 29 Oct 2024 Efficacy and adverse events data from a phase-II clinical trials in Alzheimer's disease released by Coya Therapeutics